ArticleInternational journal of nanomedicine2013
Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect.
Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- Biomedical properties of a natural dietary plant metabolite, zerumbone, in cancer therapy and chemoprevention trials.BioMed research international · 2014Pooled it
- Advancement in nanocarrier-mediated delivery of herbal bioactives: from bench to beside.Natural products and bioprospecting · 2025Review
- Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Anticancer Phytochemical Delivery: Advances, Challenges, and Future Prospects.Pharmaceutics · 2025Review
- Multifaceted Applications of Zerumbone-Loaded Metal-Organic Framework-5: Anticancer, Antibacterial, Antifungal, DNA-Binding, and Free Radical Scavenging Potentials.Molecules (Basel, Switzerland) · 2025Article
- Curcumin and EGCG combined formulation in nanostructured lipid carriers for anti-aging applications.International journal of pharmaceutics: X · 2025Article
- Enhanced Intranasal Delivery of Atorvastatin via Superparamagnetic Iron-Oxide-Loaded Nanocarriers: Cytotoxicity and Inflammation Evaluation and In Vivo, In Silico, and Network Pharmacology Study for Targeting Glioblastoma Management.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Topical Administration of Nanostructured Lipid Carriers as a Viable Approach to Reduce Inflammation: A Review.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2025Review
- Simple and Rapid Method of Microwell Array Fabrication for Drug Testing on 3D Cancer Spheroids.ACS omega · 2024Article
- M6P-modified solid lipid nanoparticles loaded with matrine for the treatment of fibrotic liver.Drug delivery · 2023Article
- Natural Compounds: Co-Delivery Strategies with Chemotherapeutic Agents or Nucleic Acids Using Lipid-Based Nanocarriers.Pharmaceutics · 2023Review
- Nanotechnology-based diagnostics and therapeutics in acute lymphoblastic leukemia: a systematic review of preclinical studies.Nanoscale advances · 2023Review
- Healthy Zerumbone: From Natural Sources to Strategies to Improve Its Bioavailability and Oral Administration.Plants (Basel, Switzerland) · 2022Review
- Development and Evaluation of Ethosomes Loaded withPharmaceutics · 2022Article
- The protective impact of adapted trimebutine maleate-loaded nanostructured lipid carriers for alleviating the severity of acute colitis.Drug delivery · 2022Article
- Development and optimization of a tamsulosin nanostructured lipid carrier loaded with saw palmetto oil and pumpkin seed oil for treatment of benign prostatic hyperplasia.Drug delivery · 2022Article
- Lipidic cubic-phase leflunomide nanoparticles (cubosomes) as a potential tool for breast cancer management.Drug delivery · 2022Article
- Unravelling the Therapeutic Potential of Nano-Delivered Functional Foods in Chronic Respiratory Diseases.Nutrients · 2022Review
- Emerging nanoformulation strategies for phytocompounds and applications from drug delivery to phototherapy to imaging.Bioactive materials · 2022Review
- Zerumbone-Loaded Nanostructured Lipid Carrier Gel Enhances Wound Healing in Diabetic Rats.BioMed research international · 2022Article
- Physicochemical characterization, cytotoxic effect and toxicity evaluation of nanostructured lipid carrier loaded with eucalyptol.BMC complementary medicine and therapies · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zerumbone, a natural dietary lipophilic compound with low water solubility (1.296 mg/L at 25°C) was used in this investigation. The zerumbone was loaded into nanostructured lipid carriers using a hot, high-pressure homogenization technique. The physicochemical properties of the zerumbone-loaded nanostructured lipid carriers (ZER-NLC) were determined. The ZER-NLC particles had an average size of 52.68 ± 0.1 nm and a polydispersity index of 0.29 ± 0.004 μm. Transmission electron microscopy showed that the particles were spherical in shape. The zeta potential of the ZER-NLC was -25.03 ± 1.24 mV, entrapment efficiency was 99.03%, and drug loading was 7.92%. In vitro drug release of zerumbone from ZER-NLC was 46.7%, and for a pure zerumbone dispersion was 90.5% over 48 hours, following a zero equation. Using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in human T-cell acute lymphoblastic leukemia (Jurkat) cells, the half maximal inhibitory concentration (IC50) of ZER-NLC was 5.64 ± 0.38 μg/mL, and for free zerumbone was 5.39 ± 0.43 μg/mL after 72 hours of treatment. This study strongly suggests that ZER-NLC have potential as a sustained-release drug carrier system for the treatment of leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.